Srinagar Observer
Sunday, June 29, 2025
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial

    The Habitual Shifts

    Assuring Crime Free Society

    Stimulating Young Energy

    An Ethical Denial

    Beating Inflation

    The Timely Exigence

    Extension in Academics

     Aiding Healthcare

    Development in Disguise

    Gender-Free Conviction

  • Edit-Oped
  • ePaper
No Result
View All Result
Srinagar Observer
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial

    The Habitual Shifts

    Assuring Crime Free Society

    Stimulating Young Energy

    An Ethical Denial

    Beating Inflation

    The Timely Exigence

    Extension in Academics

     Aiding Healthcare

    Development in Disguise

    Gender-Free Conviction

  • Edit-Oped
  • ePaper
No Result
View All Result
Srinagar Observer
No Result
View All Result
Home Business

Sanofi-GSK reports success in virus vaccine, after setback

SO NEWS Desk by SO NEWS Desk
May 17, 2021
in Business, Latest, Uncategorized
A A
0
Share on FacebookShare on TwitterWhatsApp

Paris: Sanofi and GlaxoSmithKline’s potential COVID-19 vaccine triggered strong immune responses in all adult age groups in preliminary trials after an earlier setback, boosting optimism the shot may join the fight against the pandemic this year.

After two doses of the vaccine candidate, participants showed neutralising antibodies in line with those found in people who had recovered from the disease, according to results of the Phase 2 trial released Monday.

RELATED POSTS

Delay in Rotational Headship Policy Draws Concern in Kashmir’s Medical Colleges

Rouble Nagi Art Foundation to Establish Computer Lab at Madrasa Shah Hamdan Tangdar

The drugmakers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vaccine before the end of 2021.

Regulators have already authorised a number of COVID-19 vaccines, though experts say more are needed as public health authorities around the world race to vaccinate their residents amid a pandemic that has already killed more than 3.3 million people and caused economic havoc.

The Sanofi-GSK vaccine was an important part of the European Union’s vaccination strategy, and had notably been championed by French President Emmanuel Macron’s government.

But researchers had to reformulate it after early testing produced an inadequate immune response in older people.

The Sanofi-GSK candidate joins about a dozen vaccines now undergoing late-stage trials.

The companies plan to produce up to 1 billion doses annually, and they have signed agreements to supply the US, Canada and developing countries, too. Public health experts say several vaccines will be needed to end the pandemic, because of the challenges in rapidly producing and distributing enough doses to vaccinate billions of people.

We know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines which can be stored at normal temperatures increases, said Thomas Triomphe, head of Sanofi’s vaccines unit.

The results released Monday were from a Phase 2 trial involving 722 volunteers aged 18 to 95 who were recruited in the US and Honduras.

The vaccine showed even stronger antibody results in people who had already recovered from the virus. Sanofi said that makes it a potentially strong candidate as a booster shot in the future for those who have already been vaccinated with rival products.

The late-stage trial will involve about 37,000 participants from countries around the world, the companies said. They plan to study its efficacy against the virus variant first identified in South Africa, and potentially others as well.

After the initial setback, Sanofi struck agreements to help bottle or produce rival vaccines designed by Pfizer, Moderna and Johnson&Johnson. The progress in the Sanofi-GSK vaccine will not disrupt those production plans, Triomphe said.(AP)

Related

ShareTweetSend
SO NEWS Desk

SO NEWS Desk

Related Posts

Delay in Rotational Headship Policy Draws Concern in Kashmir’s Medical Colleges

by SO NEWS Desk
June 28, 2025
0

SRINAGAR, JUNE 28 - A year after the Jammu and Kashmir government issued a landmark order mandating rotational headship in...

Rouble Nagi Art Foundation to Establish Computer Lab at Madrasa Shah Hamdan Tangdar

by SO NEWS Desk
June 27, 2025
0

KARNAH, KUPWARA | JUNE 27, 2025: In a major initiative aimed at bridging the digital divide in border areas, renowned...

Dharti Aaba Abhiyan Day-4: IEC campaign witnesses vibrant community participation in Anantnag

by SO NEWS Desk
June 18, 2025
0

ANANTNAG, JUNE 18: The ongoing 15-day Intensive Information, Education, and Communication (IEC) campaign under the Dharti Aaba Janjatiya Gramin Utkarsh...

Shakti Vijay Brigade Organizes Ex-Servicemen Rally at Tangdhar

by SO NEWS Desk
June 16, 2025
0

Dr Ashfaq Lone Tangdhar, June 16: In a significant outreach initiative, the Shakti Vijay Brigade conducted a large-scale Ex-Servicemen (ESM)...

Faz Lul Haseeb, IAS, Assumes Charge as Commissioner SMC & CEO SSCL

by SO NEWS Desk
June 16, 2025
0

SRINAGAR, JUNE 16: Shri Faz Lul Haseeb, IAS, today formally assumed charge as the Commissioner of Srinagar Municipal Corporation (SMC)...

Next Post
Doctor drawing up Covid-19 vaccine from glass phial bottle and filling syringe injection for vaccination. Close up of hand wearing protective disposable gloves in lab and holding a bottle of vaccination drugs. Hand with blue surgical gloves taking sars-coV-2 vaccine dose from vial with syringe: prevention and immunization concept.

Over 2 Cr COVID-19 vaccine doses available with states: Centre

Israel says Gaza tunnels destroyed in heavy airstrikes

Digital Edition

Srinagar Observer

Srinagar Observer is an English Newspaper based in Jammu and Kashmir

CATEGORY

  • Business
  • Edit-Oped
  • Editorial
  • Jammu
  • Kashmir
  • Latest
  • National
  • Photo Gallery
  • Sports
  • Top News
  • Uncategorized
  • World

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 9,375 other subscribers

Archives

No Result
View All Result
  • Home
  • About Us
  • Contact Us
  • Advertise

© 2024 Srinagar Observer - Designed by GITS.

No Result
View All Result
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial
  • Edit-Oped
  • ePaper

© 2024 Srinagar Observer - Designed by GITS.